Skip to main content

Table 2 Pulmonary metastases characteristics in each group (initial and second pulmonary metastasectomy)

From: Prognostic factors in pulmonary metastasectomy and efficacy of repeat pulmonary metastasectomy from colorectal cancer

Characteristics The initial pulmonary metastasectomy
n = 126
The second pulmonary metastasectomy
n = 26
p value
Diagnosis period, n (%) Synchronous 41 (32.5)
Metachronous 85 (67.5)
Number of pulmonary metastasis, n (%)   1: 89 (70.6)
2: 17 (13.5)
3: 12 (9.5)
4: 3 (2.4)
5: 2 (1.6)
1: 16 (61.5)
2: 7 (26.9)
3: 1 (3.8)
4: 2 (7.7)
0.36
Solitary 89 (70.6) 16 (61.5) 0.27
Multiple 34 (27.0) 10 (38.5)
Location, n (%) Unilateral 108 (85.7) 23 (88.5) 0.71
Bilateral 18 (14.3) 3 (11.5)
Disease free interval (days), median [range] 541.5 [0–4664] 409 [27–1334] 0.13
Maximum tumor size (mm), median [range] 12.0 [5–70] 12.0 [8–40] 1.00
Mediastinal lymph node metastasis,
n (%)
Negative 117 (92.9) 25 (96.2) 0.95
Positive 5 (4.0) 1 (3.8)
Preoperative CEA level, n (%) Normal 86 (68.3) 15 (57.7) 0.61
Elevated 36 (28.6) 8 (30.8)
Preoperative CA19-9 level, n (%) Normal 97 (77.0) 21 (80.8) 0.74
Elevated 12 (9.5) 2 (7.7)
Chemotherapy before operation, n (%) Yes 28 (22.2) 9 (34.6) 0.09
No 96 (76.2) 15 (57.7)
Chemotherapy after operation, n (%) Yes 40 (31.7) 9 (34.6) 0.50
No 74 (58.7) 12 (46.2)
Recurrence after pulmonary metastasectomy, n (%) Yes 67 (53.2) 17 (65.4) 0.07
No 59 (46.8) 7 (26.9)
Recurrent organ, n (%) Lung 47 (37.3)
Liver 12 (9.5)
Abdominal lymph node 6 (4.8)
Pelvic local recurrence 6 (4.8)
Bone 5 (4.0) Brain 5 (4.0)
Peritoneal dissemination 3 (2.4)
Pleural dissemination 2 (1.6)
Bone marrow 1 (0.8) Adrenal 1 (0.8)
Lung 13 (46.4)
Pleural dissemination 2 (7.2)
Thoracic lymph node 2 (7.2)
Liver 1 (3.6) Bone 1 (3.6)
Brain 1 (3.6) Pancreas 1 (3.6)
 
  1. CEA carcinoembryonic antigen level (normal upper limit at 5 ng/ml), CA19-9 carbohydrate antigen 19-9 level (normal upper limit at 37 ng/ml)
  2. *p < 0.05; **p < 0.01; ***p < 0.001